ADMA Biologics (ADMA) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vericel (VCEL) has outperformed ADMA Biologics (ADMA) over the past year, gaining 23.0% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with -19.8% for VCEL. ADMA Biologics is the larger company by market cap ($2.27 billion vs $2.09 billion), about 1.1 times the size.
On valuation, ADMA Biologics trades at a lower forward P/E (10.7x vs 48.2x for Vericel).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | VCEL |
|---|---|---|
| Share price | $10.14 | $40.74 |
| Market cap | $2.27B | $2.09B |
| 1-day change | -0.39% | +1.72% |
| YTD return | -44.41% | +13.14% |
| 1-year return | -27.52% | +23.04% |
| 5-year return | +821.82% | -19.79% |
| P/E ratio (TTM) | 14.49 | 86.68 |
| Forward P/E | 10.75 | 48.16 |
| EPS (TTM) | $0.70 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.46 | $49.32 |
| 52-week low | $7.21 | $28.95 |
| Distance from 52-week high | -50.44% | -17.40% |
| Analyst consensus | none | none |
| Avg. price target upside | +67.65% | +48.67% |
| Average volume | 2.63M | 502.23K |
| Shares outstanding | 223.98M | 51.21M |
| Employees | 640 | 398 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VCEL has outperformed ADMA by 50.6 percentage points over the past year.
- Vericel trades at a higher earnings multiple (86.7x vs 14.5x trailing P/E).
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 398 employees
ADMA vs VCEL FAQ
Which is bigger, ADMA Biologics or Vericel?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.27B compared with $2.09B for Vericel (VCEL).
Which stock has performed better over the past year, ADMA or VCEL?
VCEL returned +23.04% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ADMA or VCEL?
ADMA has the lower trailing P/E at 14.5, versus 86.7 for VCEL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are ADMA Biologics and Vericel in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.